Kornimate/medical-research-clean huggingface dataset:
mdr tb, levofloxacin, multi-drug-resistant pulmonary tuberculosis

Conditions: Tuberculosis, Pulmonary

Summary: estimate of clinical and microbiological efficacy of levofloxacin (tavanic) in combine therapy of mdr tb. estimate of safety of levofloxacin (tavanic) in combine therapy of mdr tb.


Eligibility criteria:
inclusion criteria: * drug-resistant pulmonary tuberculosis laboratory diagnosed exclusion criteria: * known hypersensitivity to levofloxacin, other quinolones * patient with epilepsy and central nervous system diseases * renal insufficiency with serum creatinine lower than 50 ml/min * arterial hypertension, ischemic heart disease in acute phase * gastro-intestinal diseases, liver diseases in acute phase * history of drug and alcohol abuse * patient with history of tendon disorders related to fluoroquinolone administration * pregnancy and breast-feeding women * immune system disorders related to chemotherapy, aids, long term administration of corticosteroids the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
treatment of intrauterine growth restriction with low molecular heparin.

Conditions: Intrauterine Growth Restriction

Summary: treatment of intrauterine growth restriction with low molecular weight heparin.

treatment of intrauterine growth restriction with low molecular weight heparin: randomized clinical trial (tracip study).

Eligibility criteria:
inclusion criteria: * women older than 18 years. * unique gestations * diagnosis of early placental intrauterine growth (according to delphi classification): \<32 weeks at diagnosis + doppler au with absent / reverse flow or (estimated fetal weight \<10 percentile + pulsed doppler ultrasonography) or (estimated fetal weight \<percentile 10 + pulsed uterine artery doppler). * patient giving written informed consent to participate in the study. exclusion criteria: * chromosopathies, genetic alterations or fetal malformations. * diagnostic treatment with low molecular weight heparins, oral anticoagulants or acetylsalicylic acid prior to inclusion. * history of heparin-induced thrombocytopenia. * active hemorrhage or increased risk of bleeding due to changes in hemostasis. * severe hepatic or pancreatic function disorder. * organic lesions that may bleed (eg, active peptic ulcer, hemorrhagic stroke, aneurysms, or brain tumors).
association between mitochondrial dna content and risk of gastric cancer

Conditions: Stomach Neoplasms

Summary: compelling epidemiological evidence indicates that alterations of mitochondrial dna, including mutations and abnormal content of mitochondrial dna (mtdna), are associated with the initiation and development of gastric cancer.the aim of this study was to explore association between mtdna content in peripheral blood cells could be used as a risk predictor for gastric cancer.


Eligibility criteria:
inclusion criteria: * 1.histological confirmed gastric adenocarcinoma; 2.receiving surgical resection; 3.no preoperative anticancer treatment; 4.alive at least 1 months after surgery. exclusion criteria: * 1.history of other malignancy; 2.blood transfusion within one month or prior bone marrow transplantation; 3.patients who reluctant to sign informed consent.

Keywords: mitochondrial dna copy number gastric cancer
investigating dyadic expectations about arf survivorship (ideas)

Conditions: Acute Respiratory Failure; Caregiving Stress; Mental Health Issue

Summary: the purpose of this observational study is to understand how adults who survive acute respiratory failure (arf) and the people (usually family) who support arf survivors after returning home think about the first 6 months of recovery. the study aims to find out if expectations about the recovery process after arf are associated with mental health symptoms in both survivors and the survivor's care partners. study participants will complete 3 surveys over 6 months. these surveys ask questions about participants' future expectations, feelings, and mood. surveys can be completed online, over the phone, or on paper.

the overarching objectives of the investigating dyadic expectations about arf survivorship (ideas) cohort study are to learn how expectations about arf survivorship are related to dyadic mental health symptoms and dyadic coping. specifically, the study aims are: * aim 1: to determine whether health expectations and self-efficacy after acute respiratory failure (arf) are associated with mental health outcomes in survivor-care partner dyads. * aim 2: to assess whether concordant expectations within survivor-care partner dyads are associated with better dyadic coping (primary outcome) and exploratory secondary outcomes. the term dyadic coping refers to the ways two people interact as the pair manage illness-related stressors. concordant expectations within dyads, also called shared appraisal, refers to both members of a dyad being "on the same page", and is hypothesized to lead to better dyadic coping behaviors.

Eligibility criteria:
patient inclusion criteria: * ≥18 years old * meets study definition of arf: * the study defines arf as meeting 1 of the following 3: 1. mechanical ventilation via an endotracheal tube ≥24 consecutive hours or 2. non-invasive ventilation (cpap, bipap) ≥24 consecutive hours that is not for obstructive sleep apnea or other stable use or 3. high flow nasal cannula with fraction of inspired oxygen (fio2)≥.5 and flow rate ≥ litres per minute (lpm) for ≥24 consecutive hours. * occasional rest periods of ≤1 hour are not deducted from the calculation of consecutive hours. patients who are intubated for mental status or airway obstruction are not eligible unless they have simultaneous arf. * survival to hospital discharge to home * speaks or reads english or spanish * identifies an adult who is expected to act as a primary care partner for at least the next 6 months. patient exclusion criteria: * pre-existing cognitive impairment (iq-code \>3.6) * residing in a medical institution at hospital discharge * receiving hospice care or life expectancy \<6 months * homelessness or recent history of psychosis care partner inclusion criteria: * ≥18 years old * speaks or reads english or spanish care partner exclusion criteria: * pre-existing cognitive impairment (iq-code \>3.6)

Keywords: arf survivor caregiver icu recovery dyadic coping dyadic self-efficacy
the short-term effect of eltgol on pulmonary ventilation valued through electrical impedance tomography in cystic fibrosis patients

Conditions: Cystic Fibrosis

Summary: cystic fibrosis (cf) is the most common lethal autosomal recessive disease. respiratory therapy is always recommended to the cf patient with pulmonary involvement and has differents techniques and devices, however, there is no consensus on the effectiveness of the techniques used, there is a need to determine the applicability of the therapeutic resources used. therefore, the aim of the study is to determine the short-term effectiveness of eltgol on average electrical impedance on the end of expiration (miefe) pulmonary, assessed by electrical impedance tomography (eit) in individuals with cf through a clinical trial randomized crossover. volunteers will be included with fc with moderate to severe lung disease with chest ≥ 74 cm that do not show: episode of pulmonary infectious exacerbations in the last four weeks or during the study period; cor pulmonale; facial deformity that causes air leakage; facial trauma and recent face or esophagus surgery; chest pain; hemoptysis in the last week; continued use of supplemental oxygen (\> 8 hours / day); hemoptysis; hemodynamic instability and do not understand the use and command of the techniques used. the sample is selected by convenience from the database of individuals assisted data in integrative medicine institute professor fernando figueira (imip). the research will be developed in three phases, divided into three days with an interval of at least 48 hours between phases. the first day will undergo initial assessment and in the days following the intervention by day, eltgol or acapella, in a randomized order.


Eligibility criteria:
inclusion criteria: volunteers with cystic fibrosis and lung disease with chest hemiperímetro ≥ 37 cm. exclusion criteria: episode of pulmonary infectious exacerbations in the last four weeks or during the study period; cor pulmonale; facial deformity that causes air leakage; facial trauma and recent face or esophagus surgery; chest pain; hemoptysis in the last week; continued use of supplemental oxygen (\> 8 hours / day); hemoptysis; hemodynamic instability and do not understand the use and command of the techniques used.
vitamin metabolism in kidney disease

Conditions: Kidney Failure

Summary: the purpose of this study is to evaluate the urinary excretion and renal metabolism of vitamins, in particular vitamin b12 and folate, in relation to various renal conditions involving loss of renal function and/or proteinuria.


Eligibility criteria:
inclusion criteria: * admission to the department of nephrology, aalborg hospital * elevated serum creatinine * proteinuria * informed and written consent control subjects: * normal serum creatinine and creatinine clearance * no proteinuria exclusion criteria: * vitamin supplementation (exceeding predefined values) * renal replacement therapy (dialysis)

Keywords: vitamin b12 folic acid
dignity therapy for terminally ill patients: a randomized controlled trial

Conditions: Emotional Stress; Psychological Distress; Death; Dignity

Summary: we conducted a randomized, controlled trial of dignity therapy for terminally ill patients with the aim of reducing dignity-related distress and demoralization and improving spiritual well-being.

sample size assessment: a recent meta-analysis showed that dignity interventions reach on average effect sizes of -1.01 on emotional distress (ho and shin, 2014). power analysis showed that with an alpha of 0.05 and a power of 0.80, we needed a sample of 26 participants to detect effect sizes of 1.01 and higher. plan for missing data: occasional missing values were imputed by calculating, for each participant, the average score for each subscale and then replaced. statistical analysis plan: we conducted a 2 (group) x 3 (time \[pre-treatment vs. post-treatment vs follow-up\]) repeated measures multivariate analysis of variance (manova) for a set of variables

Eligibility criteria:
inclusion criteria: * age over 18, * diagnosis of life-threatening disease with a prognosis of six months or less, * no evidence of dementia (as determined by retrospective assessments), * the ability to read and speak italian and provide written informed consent, * the availability for six to seven research encounters over the period of three weeks exclusion criteria: * psychotic illness, * dementia and severe neurological impairment

Keywords: dignity therapy; terminally ill patients; demoralization; spiritual well-being; dignity-related distress
safety and efficacy study of nvc-422 on bacteriuria in catheterized patients

Conditions: Asymptomatic Bacteriuria

Summary: the purpose of this clinical trial is to study the effects of nvc-422 instilled into the bladder in reducing bacteria in the urine.

catheter-associated urinary tract infection (cauti) is a major healthcare problem in the u.s., accounting for approximately 40% of all hospital acquired infections. microorganisms can colonize the catheter extraluminally or intraluminally, and are often protected in a biofilm environment. nearly all patients catherized for 30 days or longer will develop bacteriuria, or the presence of bacteria in normally sterile urine. ten to twenty percent of these patients will develop a symptomatic cauti. in a further 1-4%, the infection will spread into the kidneys or bloodstream, leading to potentially lethal bacteremia. currently, there is no bladder irrigation solution that can reduce or eliminate cauti. a bladder instillation solution that can keep the bladder and catheter substantially free of bacteria and biofilm is expected to provide a practical and cost-effective means of minimizing cautis. nvc-422 is a topical, non-antibiotic, fast acting, broad spectrum anti-microbial, which exhibits potential for the rapid decolonization of a range of urologic pathogens, including escherichia coli (e. coli), enterococcus spp., p. mirabilis and others. in vitro studies with nvc-422 have also shown that it is capable of penetrating a biofilm and effectively killing the contained microbes.

Eligibility criteria:
inclusion criteria: * patients or their guardians are willing and able to provide informed consent * age \> 18 years * condition requiring chronic transurethral catheterization for at least 1 month prior to enrollment * indwelling transurethral catheter not scheduled for exchange for at least 1 week from first treatment * documented asymptomatic bacteriuria as defined in the protocol * vital signs within the following limits: blood pressure 90 to 160 mm hg systolic and 50 to100 mm hg diastolic, pulse rate 45 to 100 bpm, respiratory rate 8 to 24 respirations per minute, oral body temperature 35.5ºc to 38.0ºc * screening must occur within 14 days of enrollment into the study exclusion criteria: * unwillingness/inability to fulfill the requirements of the study * history of hepatitis b or c, hiv, aids, or other immunodeficiency disease * systemic antibiotics within 7 days of enrollment * any condition that, in the opinion of the principal investigator, would make the subject unsuitable for the study or place the subject at additional risk. * any investigational drug or investigational device within 30 days of enrollment in the study * women who are pregnant or lactating; or of child-bearing potential unless using highly effective birth control method for 1 month prior to and during the study

Keywords: bacteriuria catheterized chronically catheterized
study of a cilioscleral interposition device (cid) sv22 in patients with primary open angle glaucoma

Conditions: Glaucoma, Open-Angle

Summary: the purpose of this study is to evaluate the safety and effectiveness of implanting a new version of an interposition supraciliary implant (sv22) as a stand-alone therapy for lowering intraocular pressure (iop) in patients with primary open angle glaucoma (poag) and primary narrow angle glaucoma (pnag) who have failed at least one class of topical medical therapy

57 patients will be included in this 36 months interventional study. all patients shall be indicated for glaucoma surgery alone (not combined with cataract), and will undergo incisional glaucoma therapy, including a simplified surgical technique allowing the placement of an interposition supraciliary permanent device. several patient data like safety events, iop, visual capacity or associated pharmacological treatments will be recorded pre and post-operatively all along the follow-up. purpose is to ensure device safety, and verify iop and associated pharmacological treatment reduction after surgery, and evolution along follow-up.

Eligibility criteria:
inclusion criteria: * diagnosis of primary glaucome schafer 1 to 4 * medicated iop ≥ 21 * naive of any glaucoma surgery exclusion criteria: * inflammatory, congenital, traumatic, neovascular, ice syndrome, angle closure and schaffer 1 and 2 glaucoma
real-time continuous glucose monitoring in very low birth weight neonates

Conditions: Hypoglycemia

Summary: hypoglycemia is frequent in very low birth weight (vlbw) neonates and compromises their neurological outcome. the aim of this study was to compare real-time continuous glucose monitoring system (rt-cgms) to standard method by intermittent capillary blood glucose testing in detecting and managing hypoglycemia. the investigators calculated a number of 48 neonates to be randomized between 2 ways of glucose level monitoring for their 3 first days of life : either by rt-cgms (cgm-group), or by intermittent capillary glucose testing (igm-group) associated with a blind-cgms to detect retrospectively missed hypoglycemia. the investigators' hypothesis is that in the cgm group number and duration of hypoglycemia will be lower.


Eligibility criteria:
inclusion criteria: * very low birth weight (vlbw) preterm infants (birth weight under 1500g) who were admitted before 24 hours of life in the department of neonatology of the university hospital of tours exclusion criteria: * a serious congenital abnormality, * a skin condition that contraindicated continuous glucose monitoring, * a transfer toward another hospital during the first days of life * an absence of parental agreement.

Keywords: hypoglycemia very low birth weight neonate continuous glucose monitoring
myocardial injury and major adverse outcomes in patients with covid-19

Conditions: COVID-19; Myocardial Reperfusion Injury; Cardiovascular Diseases

Summary: the study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with covid-19 treated in mount sinai hospital (msh) system. in addition, the study team will explore the association between high-sensitivity troponin i (tni) levels and clinical characteristics, biomarkers, cardiac tests data and treatment approaches to uncover the potential mechanisms responsible for covid-19 induced myocardial injury.

the study team's understanding of diagnosis, treatment and outcomes of coronavirus disease 2019 (covid-19) is rapidly evolving. first reports from china clearly indicate that older patients with underlying cardiovascular disease and/or cardiac risk factors demonstrate higher mortality rates. most recent reports provided novel insights into the incidence of myocardial injury in covid-19 patients and its association with adverse outcomes. in both studies, patients with myocardial injury manifested by elevated high-sensitivity troponin i (tni) levels had significantly higher in-hospital mortality rates compared with those without myocardial injury, (59.6 and 8.9% (3) and 51 vs 4.5 %). among patients with myocardial injury, higher levels of tni were associated with higher mortality rates. while the highest mortality rates were observed in patients with elevated tni and underlying cardiovascular disease (cvd), mortality rates were also considerable in patients with elevated tni and without prior cvd. in contrast, patients with known cardiovascular disease without tni elevation had more favorable outcomes. cardiac injury was independently associated with an increased risk of mortality in patients with covid-19. the arming reports clearly indicate that the data from larger populations from multiple centers are needed to further characterize and better understand the association between myocardial injury and adverse outcomes in covid-19 patients. ii. study aim the aim of the proposed study is to analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with covid-19 treated in mount sinai hospital (msh) system. in addition, the study team will explore the association between tni levels and clinical characteristics, biomarkers, cardiac tests data and treatment approaches to uncover the potential mechanisms responsible for covid-19 induced myocardial injury. iii. study population by october 2020, there have been 4,695 covid-19 positive patients treated in the mount sinai hospital (msh) and more than 1,1000 patients with covid-19 had been healed and discharged. all consecutive patients admitted to the msh system from february 2020 to october 2020 with laboratory-confirmed covid-19 will be included in the retrospective study.

Eligibility criteria:
inclusion criteria: * laboratory confirmed covid-19 exclusion criteria: * none

Keywords: covid-19 myocardial injury cardiovascular disease cardiac troponin
macrophage imaging using ga-mmr-vhh2 in lung cancer patients

Conditions: Non-small Cell Lung Cancer

Summary: phase ii study to evaluate the clinical potential of 68ganota-anti-mmr-vhh2 for in vivo imaging of macrophage mannose receptor (mmr)-expressing macrophages by means of positron emission tomography (pet) in patients with non-small cell lung cancer (nsclc) planned for surgical resection.


Eligibility criteria:
inclusion criteria: * patients who have given informed consent * patients at least 18 years old * patient with local, locally advanced or metastatic disease of non-small cell lung cancer, who is planned for resection or surgical biopsy of at least one lesion. in order to minimise partial volume effect, the diameter of the tumour to be resected or biopsied should be ≥ 10 mm in short axis for invaded adenopathies and ≥ 10 mm in long axis for all other types of lesions * patients who participated already in this study can be included if the subject meets all of the inclusion and none of the exclusion criteria at time of second inclusion. exclusion criteria: * eastern cooperative oncology group (ecog) performance status 3 or higher * pregnant patients * breast feeding patients * patients with any serious active infection * patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test radiopharmaceutical * patients who are unlikely to cooperate with the requirements of the study * patients who are unwilling and/or unable to give informed consent * patients at increased risk of death from a pre-existing concurrent illness

Keywords: pet/ct mmr-pet/ct macrophage pet/ct cd206
can overall adenoma detection rate replace screening adenoma detection rate ? multicenter study

Conditions: Adenoma Detection Rate; Colonoscopy

Summary: this is a prospective equivalence colonoscopy study evaluating whether overall adenoma detection rate (adr) is a reliable alternate for screening adr. overall indication includes screening, surveillance, and diagnostic indications.

this multicenter study will be conducted by 18 colonoscopists from 5 hospitals in taiwan, including evergreen general hospital, e-da hospital, e-da dachang hospital, linkou chang gung memorial hospital, and keelung chang gung memorial hospital, and plans to recruit 2700 prospective participants in a 2-year period. felix w. leung from sepulveda ambulatory care center, veterans affairs greater los angeles healthcare system (usa) will be involved in the study design, and will participate in data analyses and report preparation. consecutive patients aged ≥50 years undergoing colonoscopy are eligible for enrollment. positive fecal immunochemical test (fit+) is considered as an independent indication category and the colonoscopy indications are categorized into 4 groups: screening, surveillance, diagnostic, and fit+. overall indication will be subdivided into overall excluding fit (overall-non-fit) group and overall including fit (overall-fit) group. in this study, the investigators plan to (1) compare individual adr across 4 colonoscopy indication categories (screening, surveillance, diagnostic, fit+); (2) explore correlations between screening adr and overall-non-fit and overall-fit adrs, respectively.

Eligibility criteria:
inclusion criteria: * consecutive patients aged ≥50 years undergoing colonoscopy are eligible for enrollment. exclusion criteria: * high risk family history of colorectal cancer (crc) e.g., familial adenomatous polyposis, hereditary non-polyposis crc syndrome, multiple first degree relatives with crc, or a single first degree relative with crc at \<60 years * serrated polyposis syndrome * inflammatory bowel disease * colonoscopy to remove a large neoplastic polyps * obstructive lesions of the colon * gastrointestinal bleeding * current participation in other studies * hospitalized patients * mental retardation * pregnancy * refusal to provide a written informed consent.

Keywords: colonoscopy adenoma detection rate screening